DAMORA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
DAMORA THERAPEUTICS, INC. (DMRA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $11.07 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-10
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $11.07M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $11.42M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $8.48M.
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $11.07M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $11.42M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $8.48M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-01 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 |
| 2024-03-31 | $0.00 10-Q · filed 2024-04-29 |
| 2023-06-30 | $3.26M 10-Q · filed 2023-07-31 |
| 2023-03-31 | $1.43M 10-Q · filed 2023-04-28 |
| 2022-09-30 | $2.40K 10-Q · filed 2022-11-08 |
| 2022-03-31 | $340.27K 10-Q · filed 2022-04-29 |
| 2021-12-31 | $1.36M 10-K · filed 2024-03-08 |
| 2021-09-30 | $2.06M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $4.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $5.39M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $20.01M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |